EUVIMEDEUVIMED entdecken
Crossref

One-stop [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 total-body PET/CT examination with dual-low activity: a feasibility study

Guobing Liu, Wujian Mao, Haojun Yu, Yan Hu, Jianying Gu, Hongcheng Shi iD

European Journal of Nuclear Medicine and Molecular Imaging · 2023-07 · 50 (8) · 2271-2281

DOI: 10.1007/s00259-023-06207-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 27.03.2023. Verfasst von Guobing Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Quinolines. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: the Shanghai Municipal Key Clinical Specialty Project, the Major Science and Technology Projects for Major New Drug Creation, the Shanghai Science and Technology Committee Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Positron emission tomography/computed tomography (PET/CT) based on fibroblast activation protein inhibitors (FAPI) has shown complementary values to 2-[18F]-fluoro-2-deoxy-D-glucose ([18F]FDG) in cancer imaging. This study aimed to investigate the feasibility of a one-stop FDG-FAPI dual-tracer imaging protocol with dual-low activity for oncological imaging. METHODS: Nineteen patients with malignancies underwent one-stop [18F]FDG (0.37 MBq/kg) PET (PETFDG) and dual-tracer PET 30-40 and 50-60 min (hereafter, PETD30-40 and PETD50-60, respectively) after additional injection of [68Ga]Ga-DOTA-FAPI-04 (0.925 MBq/kg), with a single diagnostic CT to generate the PET/CT. The lesion detection rate and tumor-to-normal ratios (TNRs) of tracer uptake were compared between PETFDG/CT and PETD50-60/CT and between PETD50-60/CT and PETD30-40/CT. In addition, a visual scoring system was established to compare the lesion detectability. RESULTS: The dual-tracer PETD50-60 and PETD30-40/CT showed similar performance in detecting primary tumors but presented significantly higher lesion TNRs than PETFDG. Significantly, more metastases with higher TNRs were identified on PETD50-60 than PETFDG (491 vs. 261, P < 0.001). The dual-tracer PETD50-60 received significantly higher visual scores than single PETFDG (111 vs. 10) in demonstrating both primary tumors (12 vs. 2) and metastases (99 vs. 8). However, these differences were not significant between PETD50-60 and PETD30-40. These resulted in tumor upstaging in 44.4% patients taking PET/CT for initial assessment, and more recurrences (68 vs. 7) were identified in patients taking PET/CT for restaging, both on PETD50-60 and PETD30-40, compared to PETFDG. The reduced effective dosimetry per patient (26.2 ± 2.57 mSv) was equal to that of a single standard whole-body PET/CT. CONCLUSION: The one-stop dual-tracer dual-low-activity PET imaging protocol combines the strengths of [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 with shorter duration and lesser radiation and is thus clinically applicable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18QuinolinesHumansPositron Emission Tomography Computed TomographyFeasibility StudiesGallium RadioisotopesPositron-Emission TomographyHeterocyclic Compounds, 1-Ring

Stichwörter der Autor:innen

2-[18F]-Fluoro-2-deoxy-D-glucose ([18F]FDG)Dual-tracer imagingFibroblast activation protein inhibitor (FAPI)Positron emission tomography/computed tomography (PET/CT)

Substanzen

Fluorodeoxyglucose F18Gallium RadioisotopesQuinolines1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidHeterocyclic Compounds, 1-Ring68Ga-FAPI

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Institute of Nuclear Medicine, Fudan University, Shanghai, China.
  • Shanghai Institute of Medical Imaging, Shanghai, China.
  • Cancer Prevention and Treatment Center, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China. gu.jianying@zs-hospital.sh.cn.
  • Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China. shi.hongcheng@zs-hospital.sh.cn.

ORCID-Profile: Hongcheng Shi

Förderung

  • the Shanghai Municipal Key Clinical Specialty Project
  • the Major Science and Technology Projects for Major New Drug Creation
  • the Shanghai Science and Technology Committee Program
  • the Three-year Action Plan of Clinical Skills and Innovation of Shanghai Hospital Development Center
  • the Next Generation Information Infrastructure Construction Project founded by Shanghai Municipal Commission of Economy and Informatization

Zitieren

APA

Liu, G., Mao, W., Yu, H., Hu, Y., Gu, J., & Shi, H. (2023). One-stop [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 total-body PET/CT examination with dual-low activity: a feasibility study. European Journal of Nuclear Medicine and Molecular Imaging, 50(8), 2271-2281. https://doi.org/10.1007/s00259-023-06207-2

Vancouver

Liu G, Mao W, Yu H, Hu Y, Gu J, Shi H. One-stop [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 total-body PET/CT examination with dual-low activity: a feasibility study. European Journal of Nuclear Medicine and Molecular Imaging. 2023;50(8):2271-2281. doi:10.1007/s00259-023-06207-2

BibTeX
@article{Liu2023,
  author = {Liu, Guobing and Mao, Wujian and Yu, Haojun and Hu, Yan and Gu, Jianying and Shi, Hongcheng},
  title = {One-stop [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 total-body PET/CT examination with dual-low activity: a feasibility study},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2023},
  volume = {50},
  number = {8},
  pages = {2271--2281},
  doi = {10.1007/s00259-023-06207-2}
}
Kostenlos starten →